Psychiatrie [Psychiatry]

Détails

Ressource 1Télécharger: RMS_720-1_85 (1).pdf (292.61 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_29A1AD3D1683
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Psychiatrie [Psychiatry]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Khazaal Y., Elowe J., Kloucek P., Preisig M., Tadri M., Vandeleur C., Vandenberghe F., Verloo H., Ros T., Von Gunten A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
13/01/2021
Volume
17
Numéro
720-1
Pages
85-89
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The Covid-19 pandemic has a major impact on psychiatry by its social consequences and possible direct effect of certain forms of Covid-19 on mental health. During this crisis, the accessibility of technology meets a state of necessity, which has propelled telepsychiatry from the shadows into the light. The contribution of several technologies (i.e. virtual reality, actigraphy, computational psychiatry) combining clinical data and neuroscience underlines the great neurobehavioural variability even within the same diagnostic category, calling for greater precision in therapeutic offers as suggested e.g. by developments in neurofeedback. The place of intranasal esketamin in the panoply of antidepressent drug treatments for resistant depression has not yet been defined.
Mots-clé
COVID-19, Depressive Disorder, Treatment-Resistant/drug therapy, Humans, Ketamine/administration & dosage, Neurofeedback, Pandemics, Psychiatry/trends, Telemedicine
Pubmed
Création de la notice
26/01/2021 15:43
Dernière modification de la notice
19/01/2023 7:53
Données d'usage